查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612605

出血性疾病診斷市場：按診斷測試、適應症和最終用途分類 - 全球預測 2025-2030

Bleeding Disorder Diagnostics Market by Diagnostic Tests (Bleeding Time, Genetic Tests, Platelet Aggregation Tests), Indication (Hemophilia A & Hemophilia B, Platelet Function Disorders, Von Willebrand Disease), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，出血性疾病診斷市場價值為66287萬美元，預計2024年將達到71026萬美元，複合年成長率為7.60%，到2030年將達到110709萬美元。

出血性疾病診斷市場包括用於檢測和診斷血友病、馮維勒布蘭德病和血小板功能障礙等出血性疾病的各種檢查和工具。早期發現、有效管理和預防這些疾病併發症的需要推動了對準確診斷的需求。其應用主要集中在醫院和專業診斷中心的實驗室血液凝固檢驗、基因測試和出血評估。受益於這些診斷的最終用戶包括滿足患者更好治療結果需求的醫療保健提供者以及專注於藥物開發和臨床測試的製藥公司。

主要市場統計
基準年[2023] 66287萬美元
預測年份 [2024] 71026萬美元
預測年份 [2030] 1,107.09百萬美元
複合年成長率（%） 7.60%

關鍵的成長要素包括遺傳性疾病數量的增加、對出血性疾病的認知提高以及診斷技術的進步，例如就地檢驗和自動化。新興國家醫療基礎設施的擴張帶來了利潤豐厚的機會，基因組和蛋白質組學方法的完善也提高了診斷的準確性。公司可以透過專注於個人化醫療和開發具有成本效益的快速診斷解決方案來開拓市場。挑戰包括高級測試成本高昂、某些地區的認知度較低以及法規核准的嚴格性。

分子診斷和生物資訊學的創新代表了研究和業務擴展的有前途的途徑。重要的是要注重研究和開發，開發新的生物標記物，以便早期、準確地識別出血性疾病。此外，促進與研究機構的合作以及投資人工智慧主導的診斷工具可以推動成長。該市場表現出競爭性，老牌醫療巨頭和專注於利基市場的新興參與企業都對此表現出濃厚的興趣。然而，克服監管環境並確保廣泛的可及性仍然是持續存在的挑戰。公司應優先考慮負擔得起的測試解決方案和策略夥伴關係，以提高市場滲透率並保持競爭優勢。

市場動態：揭示快速發展的出血性疾病診斷市場的關鍵市場洞察

供需的動態交互作用正在改變出血性疾病診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 出血性疾病盛行率增加
    • 提高一般民眾和衛生專業人員對出血性疾病的認知和承諾
  • 市場限制因素
    • 與先進的出血性疾病診斷方法相關的高成本
  • 市場機會
    • 尖端技術在出血性疾病診斷藥物中的新可能性
    • 擴大照護現場出血性疾病檢測設備的採用
  • 市場問題
    • 區域醫療保健監管的監管複雜性和動態性

波特五力：駕馭出血性疾病診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解出血性疾病診斷市場的外部影響

外部宏觀環境因素在塑造出血性疾病診斷市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解出血性疾病診斷市場的競爭格局

對出血性疾病診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：出血性疾病診斷市場供應商的績效評估

FPNV 定位矩陣是評估出血性疾病診斷市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製出血性疾病診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對出血性疾病診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 出血性疾病盛行率增加
      • 公眾和醫療保健專業人員對出血性疾病的認知和承諾正在不斷增強
    • 抑制因素
      • 與先進的出血性疾病診斷方法相關的高成本
    • 機會
      • 尖端技術在出血性疾病診斷藥物中的新可能性
      • 擴大照護現場出血性疾病檢測設備的引進
    • 任務
      • 不同地區醫療保健監管的複雜性與動態性
  • 市場區隔分析
    • 診斷測試：用於識別與凝血因子相關的特定基因的突變和異常的基因測試變得越來越重要。
    • 適應症：出血性疾病診斷的重要用途，用於診斷各種類型的 VWD
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章出血性疾病診斷市場：透過診斷測試

  • 介紹
  • 出血時間
  • 基因檢測
  • 血小板凝集試驗

第7章出血性疾病診斷市場：依適應症分類

  • 介紹
  • A型血友病 A和B型血友病
  • 血小板功能障礙
  • 血管性血友病

第8章出血性疾病診斷市場：依最終用途分類

  • 介紹
  • 診斷實驗室
  • 醫院
  • 專科診所

第9章北美和南美出血性疾病診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區出血性疾病診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲出血性疾病診斷藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • ARUP 實驗室透過A型血友病診斷測試創造歷史
    • FDA核准首個針對嚴重A型血友病成年患者的基因療法
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • ARUP Laboratories
  • Baxter International Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Cepheid by Danaher Corporation
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Hyphen BioMed by Sysmex Corporation
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Precision BioLogic
  • rHEALTH
  • Siemens AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8E373E9E2067

The Bleeding Disorder Diagnostics Market was valued at USD 662.87 million in 2023, expected to reach USD 710.26 million in 2024, and is projected to grow at a CAGR of 7.60%, to USD 1,107.09 million by 2030.

The bleeding disorder diagnostics market encompasses a range of tests and tools used to detect and diagnose bleeding disorders, such as hemophilia, Von Willebrand disease, and platelet function disorders. The necessity for precise diagnostics is driven by the need for early detection, effective management, and prevention of complications associated with these conditions. Applications primarily revolve around the use of laboratory-based coagulation tests, genetic testing, and bleeding assessments in hospitals and specialized diagnostic centers. End-users benefit from these diagnostics include healthcare providers catering to patient needs for better treatment outcomes and pharmaceutical companies focusing on drug development and clinical trials.

KEY MARKET STATISTICS
Base Year [2023] USD 662.87 million
Estimated Year [2024] USD 710.26 million
Forecast Year [2030] USD 1,107.09 million
CAGR (%) 7.60%

Key growth factors include the rise in genetic disorders, increasing awareness of bleeding disorders, and advancements in diagnostic technologies such as point-of-care testing and automation. Expanding healthcare infrastructure in emerging economies presents lucrative opportunities, as does the refinement in genomic and proteomic approaches to enhance diagnostic accuracy. Companies can tap into the market by focusing on personalized medicine and developing cost-effective, rapid diagnostic solutions. Challenges include high costs of advanced tests, limited awareness in certain regions, and strict regulatory approvals.

Innovations in molecular diagnostics and bioinformatics offer promising avenues for research and business expansion. Emphasis on R&D to develop novel biomarkers for early and precise identification of bleeding disorders is critical. Additionally, fostering collaborations with research institutions and investing in AI-driven tools for diagnostics can drive growth. The market shows a competitive nature with substantial interest from both established healthcare giants and emerging players focusing on niche areas. However, navigating regulatory landscapes and ensuring broad accessibility remain persistent challenges. Companies should prioritize affordable test solutions and strategic partnerships to enhance market penetration and sustain competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bleeding Disorder Diagnostics Market

The Bleeding Disorder Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bleeding disorders
    • Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
  • Market Restraints
    • High costs associated with advanced bleeding disorder diagnostics methods
  • Market Opportunities
    • Emerging potential of advanced technologies in bleeding disorder diagnostics
    • Growing adoption of point-of-care bleeding disorder testing devices
  • Market Challenges
    • Regulatory complexities and the dynamic nature of healthcare regulations across different regions

Porter's Five Forces: A Strategic Tool for Navigating the Bleeding Disorder Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bleeding Disorder Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bleeding Disorder Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bleeding Disorder Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bleeding Disorder Diagnostics Market

A detailed market share analysis in the Bleeding Disorder Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bleeding Disorder Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bleeding Disorder Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bleeding Disorder Diagnostics Market

A strategic analysis of the Bleeding Disorder Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Tests, market is studied across Bleeding Time, Genetic Tests, and Platelet Aggregation Tests.
  • Based on Indication, market is studied across Hemophilia A & Hemophilia B, Platelet Function Disorders, and Von Willebrand Disease.
  • Based on End-use, market is studied across Diagnostic Laboratories, Hospitals, and Specialized Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders
      • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
      • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
    • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Bleeding Time
  • 6.3. Genetic Tests
  • 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A & Hemophilia B
  • 7.3. Platelet Function Disorders
  • 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
    • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ARUP Laboratories
  • 3. Baxter International Inc.
  • 4. Bayer AG
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Cepheid by Danaher Corporation
  • 7. CSL Limited
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. HORIBA, Ltd.
  • 10. Hyphen BioMed by Sysmex Corporation
  • 11. Laboratory Corporation of America Holdings
  • 12. Novo Nordisk A/S
  • 13. Precision BioLogic
  • 14. rHEALTH
  • 15. Siemens AG
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023